Session » RA – Treatments Poster II: Established Treatments

Date: Monday, November 11, 2019

Time: 9:00AM-11:00AM

Meeting: 2019 ACR/ARP Annual Meeting

9:00AM-11:00AM: Abstract Number: 1435

Acute Effects of IL-6 Blockade, TNFα Inhibitor or Glucocorticoids on Bone Turnover Markers and Wnt Inhibitors in Early Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1436

Analysis of Adverse Events of Methotrexate (MTX), bDMARDs and Tofacitinib (TOFA) Reported to Pharmaceuticals and Medical Devices Agency (PMDA), Japan

9:00AM-11:00AM: Abstract Number: 1394

Association Between Baseline Anti-CCP2 Antibody Concentration and Clinical Response After 6 Months of Treatment with Abatacept or a TNF Inhibitor in Biologic-Experienced Patients with RA: Results from a US National Observational Study

9:00AM-11:00AM: Abstract Number: 1386

Association Between Baseline Anti-citrullinated Protein Antibody Status and Response to Abatacept or Non-TNF Inhibitor Therapy in Patients with RA: Results from a US National Observational Study

9:00AM-11:00AM: Abstract Number: 1433

Association Between Seropositivity and Discontinuation of Tumor Necrosis Factor Inhibitors Due to Insufficient Response in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1401

Australian Rheumatoid Arthritis (RA) Biologic Treatment Pathways: An Australian Rheumatology Association Database (ARAD) Analysis

9:00AM-11:00AM: Abstract Number: 1416

B Cell Profile for Early Identification of Optimal Responders to TNF-inhibitors in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1407

Baricitinib Provides Better Pain Relief Across All Disease Activity Levels Compared with Placebo and Adalimumab in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1403

CDAI Analysis of Dose Escalation in a Trial of Infliximab for Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1397

Comparative Effectiveness of Tocilizumab in Combination with Methotrexate versus Tumor Necrosis Factor Inhibitors (TNFis) in Combination with Methotrexate in Patients with Rheumatoid Arthritis with Prior Exposure to TNFis

9:00AM-11:00AM: Abstract Number: 1409

Comparison of Healthcare Resource Utilization and Costs of Type 2 Diabetes Mellitus (T2DM)-Related Complications in Medicare Beneficiaries with Rheumatoid Arthritis (RA) and T2DM Who Initiated Treatment with Abatacept versus Other Targeted Disease-Modifying Anti-Rheumatic Drugs

9:00AM-11:00AM: Abstract Number: 1427

Comparison of Real-World Persistence of Subcutaneously Administered Biologic Disease-Modifying Antirheumatic Drug Therapies Among Patients with Rheumatoid Arthritis Switching from Another Biologic

9:00AM-11:00AM: Abstract Number: 1442

Comparison of Sustained Clinical Remission And/or Low Disease Activity Rate Between Rapidly and Gradually De-escalation of Abatacept in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1437

Comparison of the Efficacy and Safety of Abatacept in Rheumatoid Arthritis Patients with and Without Interstitial Lung Disease

9:00AM-11:00AM: Abstract Number: 1391

Connective Tissue Remodeling Is Differently Modulated by Tocilizumab versus Methotrexate Monotherapy in Patients with Early RA: The AMBITION Study

9:00AM-11:00AM: Abstract Number: 1419

Cost-per-Responder Analysis of Sarilumab for the Treatment of Moderately-to-Severely Active Rheumatoid Arthritis (RA)

9:00AM-11:00AM: Abstract Number: 1410

Cycling of Tumor Necrosis Factor-α (TNF-α) Inhibitors versus Switching to Different Μechanism of Αction in Rheumatoid Arthritis Patients with Inadequate Response to TNF-α Inhibitor: A Bayesian Network Meta-analysis

9:00AM-11:00AM: Abstract Number: 1438

Discontinuation of Concomitant Methotrexate in Japanese Patients with Rheumatoid Arthritis Treated with Tocilizumab: An Interventional Study

9:00AM-11:00AM: Abstract Number: 1385

Discontinuation of Oral Glucocorticoid After Initiation of Biological DMARDs Due to a Higher Dose of Methotrexate; A Retrospective Observational Study Based on Data from a Japanese Multicenter Registry Study

9:00AM-11:00AM: Abstract Number: 1384

Duration of Oral Corticosteroid Therapy Does Not Change with the Addition of a Parenteral Injection: Results from a Real-World Canadian Early RA Cohort

9:00AM-11:00AM: Abstract Number: 1425

Effect of ACPA IgM Serostatus on Efficacy Outcomes Following Treatment with Abatacept or Adalimumab: A Post Hoc Analysis of a Phase III Head-to-Head Trial

9:00AM-11:00AM: Abstract Number: 1439

Effect of Baricitinib on Functional Impairment in RA Patients with Moderate Disease Activity and an Inadequate Response to Conventional DMARDs

9:00AM-11:00AM: Abstract Number: 1421

Effect of Tocilizumab on HDL and LDL Characteristics in Patients with Rheumatoid Arthritis: Preliminary Results

9:00AM-11:00AM: Abstract Number: 1415

Effect of Tofacitinib on the Qualitative Profile of High Density Lipoproteins Molecules in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1412

Efficacy and Safety of Tofacitinib Modified-Release 11 Mg Once Daily + MTX in RA Patients with an Inadequate Response to MTX: Open-Label Phase Results from a Global Phase 3b/4 MTX Withdrawal Study

9:00AM-11:00AM: Abstract Number: 1408

Efficacy of Pharmacological Treatment in Rheumatoid Arthritis: A Systematic Literature Review Informing the 2019 Update of the EULAR Recommendations for Management of Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1413

Efficacy of Tofacitinib Monotherapy, Tofacitinib with Methotrexate and Adalimumab with Methotrexate in Patients with Early ( ≤ 2 Years) vs Established ( > 2 Years) Rheumatoid Arthritis: A Post Hoc Analysis of Data from ORAL Strategy

9:00AM-11:00AM: Abstract Number: 1402

Efficacy, Safety and Continuation Rate of Abatacept and Tocilizumab in Patients with Rheumatoid Arthritis : The Comparative Observational Study

9:00AM-11:00AM: Abstract Number: 1399

Evaluation of Effectiveness and Usage Patterns of Tofacitinib in Treatment of Rheumatoid Arthritis in Australia: An Analysis from the OPAL-QUMI Real World Dataset

9:00AM-11:00AM: Abstract Number: 1405

Expression of Uncoupling Protein-1 in Subcutaneous Fat Is Increased by Tocilizumab

9:00AM-11:00AM: Abstract Number: 1379

Glucocorticoid Dose Is Progressively Reduced in Patients with RA Receiving Sarilumab: Results from the Open-Label EXTEND Study

9:00AM-11:00AM: Abstract Number: 1383

Glucocorticoid Tapering in Monthly 1-mg Decrements Does Not Result in Clinically Manifest Adrenal Insufficiency in Patients with Rheumatoid Arthritis: Learnings from a Phase 3/4 Study

9:00AM-11:00AM: Abstract Number: 1446

Golimumab as First, Second or at Least Third Biologic Agent in Patients with Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) or Ankylosing Spondylitis (AS) – Post Hoc Analysis of a Non-Interventional Study in Germany

9:00AM-11:00AM: Abstract Number: 1420

Heterogeneity in the Pattern of Use of JAK-inhibitors Between Countries Participating in an International Collaboration of Registers of Rheumatoid Arthritis Patients (the JAK-pot Study)

9:00AM-11:00AM: Abstract Number: 1378

High Baseline Serum IL-6 Predicts Increased Sarilumab Treatment Response for Patient Reported Symptoms and Health-Related Quality of Life Among Rheumatoid Arthritis Patients with Inadequate Response to Methotrexate

9:00AM-11:00AM: Abstract Number: 1381

High Serum IgA and High Proportion of Activated Th17 and Activated Treg Cells Are Predictive Biomarkers for Remission Achievement with Abatacept in Patients with Early, Seropositive Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1393

Impact of Sarilumab on Unacceptable Pain and Inflammation Control in Moderately-to-Severely Active Rheumatoid Arthritis (RA) Patients in 3 Phase 3 Studies

9:00AM-11:00AM: Abstract Number: 1426

Impact of TNF Inhibitor Cycling with Adalimumab and Etanercept vs Switching to Tofacitinib

9:00AM-11:00AM: Abstract Number: 1406

Impact on Costs and Quality of Life over 5 Years of Treat-to-target Treatment Strategies Initiating Tocilizumab, Methotrexate or Their Combination in Early Rheumatoid Arthritis: Economic Evaluation of the U-Act-Early Trial

9:00AM-11:00AM: Abstract Number: 1434

Improvement in Matrix metalloproteinase-3 Levels at 12 Weeks Independently Predicts Achievement of Low Disease Activity at 52 Weeks in Bio-switch Patients with Rheumatoid Arthritis Treated with Abatacept

9:00AM-11:00AM: Abstract Number: 1414

Improvement of Mental Health and Quality of Life During Therapy with Tocilizumab

9:00AM-11:00AM: Abstract Number: 1441

Is Background Methotrexate Still Advantageous in Extending TNF Drug Survival in the Elderly: An Analysis of the British Society for Rheumatology Biologics Register – Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1417

Long-Term Effectiveness and Safety of Infliximab, Golimumab and Golimumab-IV in Rheumatoid Arthritis Patients from a Prospective Observational Registry

9:00AM-11:00AM: Abstract Number: 1387

Low Probability of Clinical Worsening Following Switching Biologic DMARD in Patients with RA and Partial Response to Adalimumab

9:00AM-11:00AM: Abstract Number: 1377

MTX Withdrawal in Patients with RA Who Achieve Low Disease Activity with Tofacitinib Modified-Release 11 Mg Once Daily + MTX: An Assessment of the Impact on the Short Form-36 Patient-Reported Outcome

9:00AM-11:00AM: Abstract Number: 1380

Patient Characteristics, Treatment Patterns, and Treatment Persistency in Biologic DMARD-Experienced Rheumatoid Arthritis Patients in a US RA Registry

9:00AM-11:00AM: Abstract Number: 1423

Patient-Reported Outcomes of Abatacept in Combination with MTX in Early, MTX-Naïve, ACPA Positive Patients with RA: 1-Year Results from a Phase IIIb Study

9:00AM-11:00AM: Abstract Number: 1396

Persistence of Tocilizumab Therapy Among Patients with Rheumatoid Arthritis: Data from the US-Based Corrona Rheumatoid Arthritis Registry

9:00AM-11:00AM: Abstract Number: 1411

Positivity of Anti-Ro/SSA Antibody Confer Poor Response and Persistence with Abatacept Therapy

9:00AM-11:00AM: Abstract Number: 1445

Pre-Biologic Use of Janus Kinase Inhibitors for the Treatment of Rheumatoid Arthritis in the United States

9:00AM-11:00AM: Abstract Number: 1390

Prediction of Clinical Response to Abatacept in Rheumatoid Arthritis Patients Through the Determination of Anti-Carbamylated Proteins Antibodies Levels

9:00AM-11:00AM: Abstract Number: 1430

Predictors of Response to Etanercept-Methotrexate Treatment: Post-hoc Analysis of a Randomized, Open-label Study in Latin American Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1418

Predictors of Response, Adverse Events and Treatment Retention in RA Patients Treated with Either Subcutaneous- or Intravenous- Golimumab in a Prospective, Observational Registry

9:00AM-11:00AM: Abstract Number: 1400

Real Life Retention of Tofacitinib in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1443

Real World Switching Patterns of Etanercept Original and Biosilmilar in Germany

9:00AM-11:00AM: Abstract Number: 1431

Real-Life Golimumab Persistence in Patients with Chronic Inflammatory Rheumatic Disease: Results of the GO PRACTICE Study

9:00AM-11:00AM: Abstract Number: 1422

Reduction in CD4 TEMRA Cells and Its Association with DAS28 (CRP) < 2.6 Treatment Response with Abatacept in Patients with Early, ACPA+, DMARD-Naïve RA

9:00AM-11:00AM: Abstract Number: 1440

Relationship Between Adalimumab Concentrations, Plasma Cytokines, Anti-drug Antibodies and Disease Activity in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1429

Results at 6 Months of Abatacept vs TNF-α Blockers in Patients with Severe, Long-standing, DMARDs Resistant Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1395

Risk of Immunization to Rituximab in Systemic Autoimmune Diseases and Rheumatoid Arthritis: Frequency and Risk Factors. Analysis of the Efficacy of an Alternative Treatment by Ofatumumab

9:00AM-11:00AM: Abstract Number: 1398

Sarilumab and Tocilizumab Receptor Occupancy (RO), and Effects on C-Reactive Protein (CRP) Levels, in Patients with Rheumatoid Arthritis (RA)

9:00AM-11:00AM: Abstract Number: 1432

Tapering and Discontinuing Prednisolone Without Deteriorated Disease Control by Optimizing Methotrexate in Patients with Rheumatoid Arthritis Under Stable Treatment – 2-year Results in the Real-world Clinical Practice –

9:00AM-11:00AM: Abstract Number: 1388

The Association Between Treatment of Abatacept or Other Target Disease-Modifying Anti-rheumatic Drugs and Type 2 Diabetes Mellitus (T2DM)-Related Healthcare Resource Utilization and Costs in Commercially Insured Rheumatoid Arthritis Patients with T2DM

9:00AM-11:00AM: Abstract Number: 1424

The Effect of HLA-DRB1 Risk Alleles (Shared Epitope) on Changes in Immune Cell Subsets and Disease Activity Following Treatment with Abatacept versus Adalimumab in Seropositive Biologic-Naïve Patients with Early, Moderate-to-Severe RA: Data from a Head-to-Head Single-Blinded Trial

9:00AM-11:00AM: Abstract Number: 1382

The Efficacy of Low Dose Prednisone for Remission Induction in Newly Diagnosed Rheumatoid Arthritis Patients

9:00AM-11:00AM: Abstract Number: 1392

The Relationship Between Abatacept Exposure and CD86 Receptor Occupancy in Rheumatoid Arthritis Patients Following Subcutaneous Administration and Its Association to Patient Outcomes

9:00AM-11:00AM: Abstract Number: 1428

Time to Discontinuation of Tofacitinib in Rheumatoid Arthritis Patients with and Without Methotrexate: Results from a Rheumatoid Arthritis Cohort

9:00AM-11:00AM: Abstract Number: 1444

Tofacitinib in Patients with Rheumatoid Arthritis and Indicative of Depression And/or Anxiety: A Post Hoc Analysis of Phase 3 and Phase 3b/4 Clinical Trials

9:00AM-11:00AM: Abstract Number: 1389

Treatment Response to Biologic DMARDs in Patients with RA: A Retrospective Analysis of the RISE Registry

9:00AM-11:00AM: Abstract Number: 1404

Treatments Patterns Among Patients with Rheumatoid Arthritis Treated with a Biologic Disease-modifying Anti-rheumatic Drug: A Nation-wide Study in Korea

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].